Goodrx Holdings (GDRX) financial statements
Goodrx Holdings reported revenue of $797M in fiscal 2025, up 18.0% a year over 7 years.
Net income was $30M and the operating margin 11.0%, against 31.0% in 2018.
Free cash flow was $94M, and the company returned $216M in net buybacks.
The diluted share count rose 202% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Goodrx Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $250M | $388M | $551M | $745M | $767M | $750M | $792M | $797M |
| Cost of revenue | $6M | $14M | $30M | $47M | $65M | $67M | $48M | $58M |
| Gross profit | $243M | $374M | $521M | $699M | $701M | $683M | $744M | $739M |
| Research and development | $44M | $29M | $62M | $126M | $143M | $136M | $124M | $121M |
| Selling, general and admin | $113M | $192M | $717M | $525M | $502M | $467M | $485M | $446M |
| Operating income | $77M | $140M | -$276M | $13M | $2M | -$27M | $66M | $87M |
| Interest expense | $22M | $50M | $28M | $24M | $34M | $57M | $53M | $43M |
| Pre-tax income | $52M | $83M | -$303M | -$10M | -$23M | -$56M | $31M | $57M |
| Income tax | $9M | $17M | -$10M | $15M | $10M | -$47M | $15M | $26M |
| Net income | $44M | $66M | -$294M | -$25M | -$33M | -$9M | $16M | $30M |
| EPS (diluted) | $0.12 | $0.18 | -$1.07 | -$0.06 | -$0.08 | -$0.02 | $0.04 | $0.09 |
| Diluted shares | 118M | 231M | 275M | 410M | 413M | 410M | 392M | 357M |
| Gross margin | 97.6% | 96.4% | 94.6% | 93.7% | 91.5% | 91.1% | 93.9% | 92.8% |
| Operating margin | 31.0% | 36.0% | -50.1% | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% |
| Net margin | 17.6% | 17.0% | -53.3% | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% |
Balance sheet
Fiscal years, from Goodrx Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $35M | $26M | $969M | $941M | $757M | $672M | $448M | $262M |
| Receivables | — | $48M | $69M | $118M | $117M | $144M | $146M | $236M |
| Total current assets | — | $87M | $1.1B | $1.1B | $920M | $873M | $659M | $643M |
| Property, plant and equipment | — | $2M | $23M | $22M | $20M | $16M | $13M | $12M |
| Goodwill | $220M | $236M | $261M | $330M | $412M | $411M | $411M | $430M |
| Total assets | — | $387M | $1.5B | $1.6B | $1.6B | $1.6B | $1.4B | $1.4B |
| Total current liabilities | — | $33M | $60M | $81M | $76M | $123M | $124M | $246M |
| Long-term debt | — | $664M | $660M | $656M | $652M | $648M | $487M | $483M |
| Total liabilities | — | $737M | $759M | $776M | $790M | $827M | $663M | $788M |
| Shareholders' equity | -$1.2B | -$1.1B | $711M | $832M | $815M | $762M | $725M | $616M |
| Net debt | -$35M | $645M | -$302M | -$278M | -$98M | -$16M | $43M | $226M |
Cash flow
Fiscal years, from Goodrx Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45M | $83M | $131M | $179M | $147M | $138M | $184M | $168M |
| Capital spending | $3M | $6M | $36M | $34M | $55M | $56M | $70M | $74M |
| Free cash flow | $42M | $78M | $96M | $144M | $92M | $83M | $114M | $94M |
| Stock-based compensation | $2M | $4M | $397M | $160M | $120M | $105M | $99M | $77M |
| Dividends paid | $1.3B | — | — | — | — | — | — | — |
| Share buybacks (net) | — | — | $0 | $0 | -$102M | -$104M | -$159M | -$216M |
| Net borrowing | $607M | -$57M | -$7M | -$7M | -$7M | -$5M | -$167M | -$5M |
| Free cash flow margin | 16.8% | 20.0% | 17.3% | 19.4% | 11.9% | 11.0% | 14.3% | 11.8% |
| Dividends per share | $11.38 | — | — | — | — | — | — | — |
Questions
What was Goodrx Holdings's revenue in 2025?
$797M in fiscal 2025, from its 10-K filing.
How much free cash flow does Goodrx Holdings generate?
$94M in fiscal 2025 (operating cash flow minus capital spending).
From Goodrx Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.